By Bill Berkrot (Reuters) - Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial. Patients with the blood cancer who received the Kyprolis regimen for 18 months also had a longer duration of response and reported better health-related quality of life, data presented on Saturday showed. Overall survival data was not yet available, but researchers reported a trend toward improved survival seen with the three-drug regimen. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment